Corsair Pharma

Executive Summary

Corsair Pharma is a private biotechnology company focused on improving the therapeutic profile of existing medications through innovative delivery systems. Its lead program is a proprietary transdermal patch delivering a treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH). Treprostinil is a well-established vasodilator, but current formulations require continuous subcutaneous infusion or frequent oral dosing, leading to tolerability and compliance issues. Corsair's patch aims to provide sustained, non-invasive drug delivery, potentially offering patients a safer, more convenient, and better-tolerated alternative. The company is based in Cambridge, Massachusetts, and was founded in 2018. Corsair is currently in Phase 1 clinical development, evaluating the safety and pharmacokinetics of its transdermal patch. If successful, the product could capture a significant share of the PAH market, which includes several approved treprostinil products generating billions in annual sales. However, as a preclinical-to-early-clinical stage company, Corsair faces high technical and regulatory risks, including patch adhesion, consistent drug release, and skin tolerability. The company's progress will hinge on positive Phase 1 data and securing partnerships or funding for later-stage trials. Its valuation and financing history are not disclosed, but the unmet need in PAH supports upside potential.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and pharmacokinetic data readout70% success
• Q2 2027FDA feedback or IND clearance for Phase 280% success
• H1 2027Strategic partnership or licensing agreement50% success